Wikipedia
Actavis Generics (formerly known as Watson Pharmaceuticals and Actavis, plc, prior to the acquisition of Allergan, inc) is a global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.
Actavis, plc markets brand products through six franchises in key therapeutic categories including: Aesthetics/Dermatology/Plastic Surgery; Neurosciences/CNS; Eye Care; Women’s Health and Urology; GI and Cystic Fibrosis; and Cardiovascular Disease and Infectious Disease. The company's products include Botox, Namenda, Restasis, Linzess, Bystolic, Juvederm, Latisse, Lo Loestrin Fe, Estrace, Teflaro, Dalvance, Ozurdex, Optive, Natrelle, Viibryd, Liletta, Saphris, Enablex, Actonel, Androderm, Gelnique and others.
Actavis, plc also operates the world's third-largest generics business. The company is ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets. Actavis also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, the world's largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers more than 200 products. Actavis, plc is also developing biosimilars products in oncology and other therapeutic categories, and currently has five biosimilar products in development. Actavis, plc has more than 40 manufacturing and distribution facilities around the world, with a capacity of approximately 40 billion units annually. Actavis Global Operations also includes Anda, Inc., the fourth-largest U.S. generic pharmaceutical product distributor in the United States.
On June 15, 2015, Actavis, plc changed its name to Allergan, plc, but the company's U.S. and Canadian generics business will continue to operate under the Actavis name.
In July 2015, Allergan, Plc announced it would sell its Generics division of the company to Teva Pharmaceuticals for $40.5 billion, a transaction proposed for completion by the first quarter of 2016.